Pancreatic Cancer Stocks List

Related ETFs - A few ETFs which own one or more of the above listed Pancreatic Cancer stocks.

Recent Signals

Date Stock Signal Type
2021-05-12 AIKI 180 Bearish Setup Bearish Swing Setup
2021-05-12 AIKI MACD Bearish Signal Line Cross Bearish
2021-05-12 AIM Bollinger Band Squeeze Range Contraction
2021-05-12 AIM Non-ADX 1,2,3,4 Bearish Bearish Swing Setup
2021-05-12 AIM Stochastic Reached Oversold Weakness
2021-05-12 APTO Narrow Range Bar Range Contraction
2021-05-12 APTO 180 Bearish Setup Bearish Swing Setup
2021-05-12 APTO NR7 Range Contraction
2021-05-12 CRNX Fell Below 50 DMA Bearish
2021-05-12 EXAS New Downtrend Bearish
2021-05-12 EXAS Lower Bollinger Band Walk Weakness
2021-05-12 EXAS Calm After Storm Range Contraction
2021-05-12 EXAS NR7 Range Contraction
2021-05-12 FGEN Pocket Pivot Bullish Swing Setup
2021-05-12 FGEN Crossed Above 20 DMA Bullish
2021-05-12 INCY Crossed Above 50 DMA Bullish
2021-05-12 ISR Bollinger Band Squeeze Range Contraction
2021-05-12 ISR 180 Bearish Setup Bearish Swing Setup
2021-05-12 MYGN Lower Bollinger Band Walk Weakness
2021-05-12 MYGN Pocket Pivot Bullish Swing Setup
2021-05-12 NVCR Non-ADX 1,2,3,4 Bullish Bullish Swing Setup
2021-05-12 NVCR NR7 Range Contraction
2021-05-12 ONTX Stochastic Buy Signal Bullish
2021-05-12 ONTX Pocket Pivot Bullish Swing Setup
2021-05-12 OPK Lower Bollinger Band Walk Weakness
2021-05-12 PBLA 180 Bearish Setup Bearish Swing Setup
2021-05-12 PPBT New 52 Week Closing Low Bearish
2021-05-12 SGEN Crossed Above 20 DMA Bullish
2021-05-12 SGEN Crossed Above 50 DMA Bullish
2021-05-12 SGEN MACD Bullish Signal Line Cross Bullish

Recent News for Pancreatic Cancer Stocks

Date Stock Title
May 13 EXAS Cathie Wood Piles Up Palantir For Third Day In A Row, Adding $39M Worth Of Shares
May 12 FGEN ROSEN, SKILLED INVESTOR COUNSEL, Encourages FibroGen, Inc. Investors to Secure Counsel Before Important June 11 Deadline in Securities Class Action – FGEN
May 12 FGEN HAGENS BERMAN, NATIONAL TRIAL ATTORNEYS, Updates ACAD, FGEN, RMO Investors on Securities Class Actions and Application Deadlines, Encourages Investors with Losses to Contact the Firm Now
May 12 PBLA Panbela Therapeutics reports Q1 results
May 12 INCY Data From Incyte’s Oncology Portfolio Accepted for Presentation at the 2021 EHA Virtual Congress
May 12 PBLA Panbela Provides Business Update and Reports Q1 2021 Financial Results
May 12 MYGN Glenview's Robbins pitches SPACs Fortress Value, Thoma Bravo at Sohn conference
May 12 FGEN LAWSUITS FILED AGAINST FGEN, CCIV and SKLZ - Jakubowitz Law Pursues Shareholders Claims
May 12 NVCR Could Novocure Be a Millionaire-Maker Stock?
May 12 FGEN FGEN CLASS ACTION ALERT: Hagens Berman, National Trial Attorneys, Recommends FibroGen (FGEN) Investors with Losses to Contact the Firm
May 12 AIKI AIkido Pharma Inc. to Present at the Benzinga Global Small Cap Conference, the Investor Summit Group's Conference, and the LD Micro Invitational Conference
May 12 FGEN SHAREHOLDER ACTION REMINDER: The Schall Law Firm Files Securities Class Action Suit with Extended Class Period Against FibroGen, Inc.
May 12 FGEN The Klein Law Firm Reminds Investors of Class Actions on Behalf of Shareholders of CYDY, RIDE and FGEN
May 12 APTO Aptose to Present at Upcoming Investor Conferences
May 12 FGEN CLASS ACTION UPDATE for CYDY, FGEN and CAN: Levi & Korsinsky, LLP Reminds Investors of Class Actions on Behalf of Shareholders
May 12 FGEN CLASS ACTION UPDATE for FGEN, PCT and SKLZ: Levi & Korsinsky, LLP Reminds Investors of Class Actions on Behalf of Shareholders
May 12 PBLA Earnings Scheduled For May 12, 2021
May 12 INCY Should Weakness in Incyte Corporation's (NASDAQ:INCY) Stock Be Seen As A Sign That Market Will Correct The Share Price Given Decent Financials?
May 11 FGEN FGEN CLASS ACTION ALERT: Kessler Topaz Meltzer & Check, LLP Reminds FibroGen, Inc. Shareholders of Securities Fraud Class Action Lawsuit
May 11 FGEN CLASS ACTION UPDATE for ACAD, FGEN, RMO: Hagens Berman Updates Investors on Securities Class Actions, Advises Investors with Losses to Contact the Firm

Pancreatic cancer arises when cells in the pancreas, a glandular organ behind the stomach, begin to multiply out of control and form a mass. These cancerous cells have the ability to invade other parts of the body. There are a number of types of pancreatic cancer. The most common, pancreatic adenocarcinoma, accounts for about 85% of cases, and the term "pancreatic cancer" is sometimes used to refer only to that type. These adenocarcinomas start within the part of the pancreas which makes digestive enzymes. Several other types of cancer, which collectively represent the majority of the non-adenocarcinomas, can also arise from these cells. One to two percent of cases of pancreatic cancer are neuroendocrine tumors, which arise from the hormone-producing cells of the pancreas. These are generally less aggressive than pancreatic adenocarcinoma.Signs and symptoms of the most common form of pancreatic cancer may include yellow skin, abdominal or back pain, unexplained weight loss, light-colored stools, dark urine and loss of appetite. There are usually no symptoms in the disease's early stages, and symptoms that are specific enough to suggest pancreatic cancer typically do not develop until the disease has reached an advanced stage. By the time of diagnosis, pancreatic cancer has often spread to other parts of the body.Pancreatic cancer rarely occurs before the age of 40, and more than half of cases of pancreatic adenocarcinoma occur in those over 70. Risk factors for pancreatic cancer include tobacco smoking, obesity, diabetes, and certain rare genetic conditions. About 25% of cases are linked to smoking, and 5–10% are linked to inherited genes. Pancreatic cancer is usually diagnosed by a combination of medical imaging techniques such as ultrasound or computed tomography, blood tests, and examination of tissue samples (biopsy). The disease is divided into stages, from early (stage I) to late (stage IV). Screening the general population has not been found to be effective.The risk of developing pancreatic cancer is lower among non-smokers, and people who maintain a healthy weight and limit their consumption of red or processed meat. A smoker's chance of developing the disease decreases if they stop smoking, and almost returns to that of the rest of the population after 20 years. Pancreatic cancer can be treated with surgery, radiotherapy, chemotherapy, palliative care, or a combination of these. Treatment options are partly based on the cancer stage. Surgery is the only treatment that can cure pancreatic adenocarcinoma, and may also be done to improve quality of life without the potential for cure. Pain management and medications to improve digestion are sometimes needed. Early palliative care is recommended even for those receiving treatment that aims for a cure.In 2015, pancreatic cancers of all types resulted in 411,600 deaths globally. Pancreatic cancer is the fifth most common cause of death from cancer in the United Kingdom, and the fourth most common in the United States. The disease occurs most often in the developed world, where about 70% of the new cases in 2012 originated. Pancreatic adenocarcinoma typically has a very poor prognosis: after diagnosis, 25% of people survive one year and 5% live for five years. For cancers diagnosed early, the five-year survival rate rises to about 20%. Neuroendocrine cancers have better outcomes; at five years from diagnosis, 65% of those diagnosed are living, though survival varies considerably depending on the type of tumor.

More about Pancreatic Cancer
Browse All Tags